Trial Profile
Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Adult-onset Still's disease
- Focus Therapeutic Use
- Acronyms CONSIDER
- 06 Jun 2020 Results of 24 weeks treatment presented at the 21st Annual Congress of the European League Against Rheumatism.
- 13 May 2020 Primary endpoint (Efficacy of canakinumab with a clinically-significant reduction in disease activity) has not been met as per results published in the Annals of the Rheumatic Diseases
- 13 May 2020 Results published in the Annals of the Rheumatic Diseases